ticlopidine has been researched along with Diseases, Peripheral Vascular in 92 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding." | 9.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| "We evaluated the plasma concentrations of platelet activation markers and platelet-derived microparticles (PMP) in patients with connective tissue diseases complaining of peripheral circulation disorders (n = 16) and studied the effect of ticlopidine hydrochloride (ticlopidine) on PMP generation." | 7.70 | Effect of ticlopidine on platelet-derived microparticles in patients with connective tissue diseases. ( Fukuhara, S; Kagawa, H; Nagahama, M; Nomura, S; Ozaki, Y, 1999) |
| " The rate of cardiovascular death, MI, or stroke was significantly lower in the clopidogrel plus aspirin arm than in the placebo plus aspirin arm: 7." | 5.12 | Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Hamm, CW; Hankey, GJ; Hu, T; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2007) |
| "We studied 18 558 patients with ischemic stroke, myocardial infarction, or peripheral arterial disease who participated in the trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE), a study that compared the occurrence of ischemic stroke, myocardial infarction, or vascular death under randomized treatment with aspirin or clopidogrel." | 5.11 | Leukocyte count as an independent predictor of recurrent ischemic events. ( Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C, 2004) |
| " We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding." | 5.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| "EMATAP, a randomized stratified, placebo-controlled double-blind multicentre trial was performed in Argentina in order to confirm the effect of ticlopidine in the prevention of thrombotic events in patients with intermittent claudication." | 5.07 | Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. ( Blanchard, J; Carreras, LO; Kindermans, M, 1994) |
| " Monotherapy with either aspirin or clopidogrel, reduces the rate of stroke, myocardial infarction, and cardiovascular death in patients suffering from peripheral arterial disease." | 4.85 | Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? ( Milani, RV, 2009) |
| "Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| "Intermittent claudication has changed from being only a disabling symptom to being an indication for secondary prevention of coronary and cerebrovascular events." | 3.77 | [Role of antiaggregants in the treatment of arterial diseases of the lower limbs]. ( Boissel, JP, 1991) |
| "Patients with ischemic stroke enrolled in the Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH) study underwent long-term prospective assessment of their modified Rankin Scale (mRS) score." | 3.74 | Rate, degree, and predictors of recovery from disability following ischemic stroke. ( Bego, G; Carita, P; Gabriel, S; Hakimi, Z; Hankey, GJ; Spiesser, J, 2007) |
| "We studied 137 patients undergoing antiplatelet therapy with clopidogrel and 336 patients with aspirin for the occurrence of neurological events (ischemic stroke and/or carotid revascularization)." | 3.73 | Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. ( Amighi, J; Brunner, M; Exner, M; Felber, K; Funk, M; Mannhalter, C; Minar, E; Mlekusch, W; Müller, M; Sabeti, S; Schillinger, M; Ziegler, S, 2005) |
| "We evaluated the plasma concentrations of platelet activation markers and platelet-derived microparticles (PMP) in patients with connective tissue diseases complaining of peripheral circulation disorders (n = 16) and studied the effect of ticlopidine hydrochloride (ticlopidine) on PMP generation." | 3.70 | Effect of ticlopidine on platelet-derived microparticles in patients with connective tissue diseases. ( Fukuhara, S; Kagawa, H; Nagahama, M; Nomura, S; Ozaki, Y, 1999) |
| "(1) Aspirin reduces the risk of myocardial infarction in men over 40 with no history of cardiovascular disease, and in hypertensive patients of both sexes over that age." | 3.70 | Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention. ( , 2000) |
| "To assess the effect of ticlopidine on the cutaneous circulation, 25 patients with lower limb ischemia were investigated just before and at two hours after being given a 200 mg oral dose of ticlopidine." | 3.68 | Effect of ticlopidine on the cutaneous circulation in peripheral vascular disease. ( Iwai, T; Qian, S, 1993) |
| "Sarpogrelate is a selective 5-hydroxytryptamine (5-HT) receptor subtype 2A antagonist which blocks 5-HT induced platelet aggregation and proliferation of vascular smooth muscle cells." | 2.80 | Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results. ( Chen, YX; Gu, YQ; Hu, HJ; Li, XQ; Liu, CW; Song, XJ; Tian, HY; Wang, WD; Zhao, JC, 2015) |
| "Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events." | 2.68 | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. ( , 1996) |
| "As well as initiating thrombus formation at the site of a ruptured atherosclerotic plaque, platelets play a key role in vascular inflammation, through release of their own pro-inflammatory mediators and interactions with other relevant cell types (endothelial cells, leukocytes, and smooth muscle cells)." | 2.44 | Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. ( Badimon, JJ; Bhatt, DL; Herbert, JM; Lüscher, TF; Steinhubl, SR, 2007) |
| "Ticlopidine-induced aplastic anemia (TIAA) is considered very uncommon." | 2.41 | Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases. ( Fragopanagou, E; Galani, A; Giannakoulas, N; Kouraklis-Symeonidis, A; Matsouka, P; Seimeni, U; Symeonidis, A; Tiniakou, M; Zoumbos, N, 2002) |
| " These results demonstrated that long-term administration of clopidogrel was effective in preventing ischaemic events in patients with atherosclerotic vascular disease including PAD." | 2.41 | Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy. ( Hiatt, WR, 2002) |
| "No or only a mild restenosis developed in 27 patients." | 1.32 | Clinical and angiographic outcome after interventional treatment of the iliac arteries with a new carbofilm coated stent: preliminary results. ( Butz, B; Feuerbach, S; Lenhart, M; Link, J; Paetzel, C; Pfister, K; Schleicher, T; Stern, U, 2004) |
| " It is indicated, at a dosage of 75 mg/day, for the reduction of atherosclerotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction or established peripheral vascular disease." | 1.31 | [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. ( Scheen, AJ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (20.65) | 18.2507 |
| 2000's | 58 (63.04) | 29.6817 |
| 2010's | 15 (16.30) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saadeh, C | 2 |
| Sfeir, J | 2 |
| Karnabatidis, D | 2 |
| Spiliopoulos, S | 2 |
| Pastromas, G | 2 |
| Kitrou, P | 2 |
| Christeas, N | 1 |
| Katsanos, K | 2 |
| Siablis, D | 2 |
| Diamantopoulos, A | 1 |
| Stone, DH | 1 |
| Nolan, BW | 1 |
| Cronenwett, JL | 1 |
| Chen, YX | 1 |
| Wang, WD | 1 |
| Song, XJ | 1 |
| Gu, YQ | 1 |
| Tian, HY | 1 |
| Hu, HJ | 1 |
| Zhao, JC | 1 |
| Li, XQ | 1 |
| Liu, CW | 1 |
| Ghantous, AE | 1 |
| Ferneini, EM | 1 |
| Cacoub, PP | 1 |
| Bhatt, DL | 4 |
| Steg, PG | 2 |
| Topol, EJ | 4 |
| Creager, MA | 2 |
| Milani, RV | 1 |
| Mohler, ER | 1 |
| Wilson, AM | 1 |
| Brittenden, J | 1 |
| Bachoo, P | 1 |
| Ford, I | 1 |
| Nixon, GF | 1 |
| Linnemann, B | 3 |
| Schwonberg, J | 3 |
| Rechner, AR | 1 |
| Mani, H | 3 |
| Lindhoff-Last, E | 3 |
| Toennes, SW | 2 |
| Poredos, P | 1 |
| Jezovnik, MK | 1 |
| Belch, JJ | 1 |
| Dormandy, J | 1 |
| Biasi, GM | 1 |
| Biasi, BM | 1 |
| Cairols, M | 1 |
| Diehm, C | 1 |
| Eikelboom, B | 1 |
| Golledge, J | 1 |
| Jawien, A | 1 |
| Lepäntalo, M | 1 |
| Norgren, L | 1 |
| Hiatt, WR | 3 |
| Becquemin, JP | 2 |
| Bergqvist, D | 2 |
| Clement, D | 1 |
| Baumgartner, I | 1 |
| Minar, E | 2 |
| Stonebridge, P | 1 |
| Vermassen, F | 1 |
| Matyas, L | 1 |
| Leizorovicz, A | 1 |
| Ferreira-González, I | 1 |
| Marsal, JR | 1 |
| Ribera, A | 1 |
| Permanyer-Miralda, G | 1 |
| García-Del Blanco, B | 1 |
| Martí, G | 1 |
| Cascant, P | 1 |
| Martín-Yuste, V | 1 |
| Brugaletta, S | 1 |
| Sabaté, M | 1 |
| Alfonso, F | 1 |
| Capote, ML | 1 |
| De La Torre, JM | 1 |
| Ruíz-Lera, M | 1 |
| Sanmiguel, D | 1 |
| Cárdenas, M | 1 |
| Pujol, B | 1 |
| Baz, JA | 1 |
| Iñiguez, A | 1 |
| Trillo, R | 1 |
| González-Béjar, O | 1 |
| Casanova, J | 1 |
| Sánchez-Gila, J | 1 |
| García-Dorado, D | 1 |
| Thomson, L | 1 |
| Monaco, M | 1 |
| Di Tommaso, L | 1 |
| Pinna, GB | 1 |
| Lillo, S | 1 |
| Schiavone, V | 1 |
| Stassano, P | 1 |
| Allemang, MT | 1 |
| Rajani, RR | 1 |
| Nelson, PR | 1 |
| Hingorani, A | 1 |
| Kashyap, VS | 2 |
| Maier, C | 1 |
| Gleim, M | 1 |
| Weiss, T | 1 |
| Stachetzki, U | 1 |
| Nicolas, V | 1 |
| Zenz, M | 1 |
| Symeonidis, A | 1 |
| Kouraklis-Symeonidis, A | 1 |
| Seimeni, U | 1 |
| Galani, A | 1 |
| Giannakoulas, N | 1 |
| Fragopanagou, E | 1 |
| Tiniakou, M | 1 |
| Matsouka, P | 1 |
| Zoumbos, N | 1 |
| Pasqualini, L | 1 |
| Pirro, M | 1 |
| Lombardini, R | 1 |
| Ciuffetti, G | 1 |
| Dragani, P | 1 |
| Mannarino, E | 1 |
| Matsagas, MI | 3 |
| Jagroop, IA | 3 |
| Mikhailidis, DP | 6 |
| Geroulakos, G | 4 |
| Dörffler-Melly, J | 1 |
| Schmidli, J | 1 |
| Mahler, F | 1 |
| Matsagas, M | 1 |
| Self, R | 1 |
| Brandner, B | 1 |
| Smout, JD | 1 |
| Shenton, BK | 1 |
| Stansby, G | 2 |
| Grau, AJ | 1 |
| Boddy, AW | 1 |
| Dukovic, DA | 1 |
| Buggle, F | 1 |
| Lichy, C | 1 |
| Brandt, T | 1 |
| Hacke, W | 3 |
| Federman, DG | 1 |
| Bravata, DM | 1 |
| Kirsner, RS | 1 |
| Aronow, WS | 1 |
| Tran, H | 1 |
| Anand, SS | 1 |
| Butz, B | 1 |
| Paetzel, C | 1 |
| Stern, U | 1 |
| Schleicher, T | 1 |
| Pfister, K | 1 |
| Link, J | 1 |
| Feuerbach, S | 1 |
| Lenhart, M | 1 |
| Daskalopoulou, SS | 1 |
| Cavendish, JJ | 2 |
| Safani, M | 1 |
| Garcia, S | 1 |
| Canoniero, MJ | 1 |
| Chirinos, JA | 1 |
| de Marchena, E | 1 |
| Salerno, T | 1 |
| Ferreira, A | 1 |
| Eriksson, P | 1 |
| Mukherjee, D | 1 |
| Moliterno, DJ | 1 |
| Brennan, DM | 1 |
| Ziada, K | 1 |
| Cho, L | 1 |
| Steinhubl, SR | 3 |
| Madi-Jebara, S | 1 |
| Rkeiby-Kassabian, N | 1 |
| Yazigi, A | 1 |
| Ziegler, S | 1 |
| Schillinger, M | 1 |
| Funk, M | 1 |
| Felber, K | 1 |
| Exner, M | 1 |
| Mlekusch, W | 1 |
| Sabeti, S | 1 |
| Amighi, J | 1 |
| Brunner, M | 1 |
| Müller, M | 1 |
| Mannhalter, C | 1 |
| Hansen, DB | 1 |
| Eikelboom, JW | 1 |
| Hankey, GJ | 3 |
| Thom, J | 1 |
| Claxton, A | 1 |
| Yi, Q | 1 |
| Gilmore, G | 1 |
| Staton, J | 1 |
| Barden, A | 1 |
| Norman, PE | 1 |
| Tulsyan, N | 1 |
| Ouriel, K | 1 |
| Uemura, T | 1 |
| Takamatsu, H | 1 |
| Kawasaki, T | 1 |
| Taniguchi, M | 1 |
| Yamamoto, E | 1 |
| Tomura, Y | 1 |
| Uchida, W | 1 |
| Miyata, K | 1 |
| Krantz, MJ | 1 |
| Wong, S | 1 |
| Morel-Kopp, MC | 1 |
| Chen, Q | 1 |
| Appleberg, M | 1 |
| Ward, CM | 1 |
| Lewis, DR | 1 |
| Hackam, DG | 1 |
| Rao, AK | 1 |
| Vaidyula, VR | 1 |
| Bagga, S | 1 |
| Jalagadugula, G | 1 |
| Gaughan, J | 1 |
| Wilhite, DB | 1 |
| Comerota, AJ | 2 |
| Priollet, P | 1 |
| de Pouvourville, G | 1 |
| Spiesser, J | 1 |
| Hakimi, Z | 1 |
| Bego, G | 1 |
| Carita, P | 1 |
| Gabriel, S | 1 |
| Flather, MD | 1 |
| Berger, PB | 1 |
| Black, HR | 1 |
| Boden, WE | 1 |
| Cacoub, P | 1 |
| Cohen, EA | 1 |
| Easton, JD | 1 |
| Hamm, CW | 1 |
| Johnston, SC | 1 |
| Mak, KH | 1 |
| Mas, JL | 1 |
| Montalescot, G | 1 |
| Pearson, TA | 1 |
| Weber, MA | 1 |
| Fabry-Ribaudo, L | 1 |
| Hu, T | 1 |
| Fox, KA | 1 |
| Badimon, JJ | 1 |
| Herbert, JM | 1 |
| Lüscher, TF | 1 |
| Anand, S | 1 |
| Yusuf, S | 1 |
| Xie, C | 1 |
| Pogue, J | 1 |
| Eikelboom, J | 1 |
| Budaj, A | 1 |
| Sussex, B | 1 |
| Liu, L | 1 |
| Guzman, R | 1 |
| Cina, C | 1 |
| Crowell, R | 1 |
| Keltai, M | 1 |
| Gosselin, G | 1 |
| Nayak, KR | 1 |
| Urbanek, DA | 1 |
| Kauert, GF | 1 |
| Cave, AJ | 1 |
| Cox, DW | 1 |
| Vicaruddin, O | 1 |
| Thakur, S | 1 |
| Nagarakanti, R | 1 |
| Sodhi, S | 1 |
| Lee, R | 1 |
| Ezekowitz, M | 1 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
| Andreozzi, GM | 2 |
| Arosio, E | 2 |
| Martini, R | 2 |
| Verlato, F | 1 |
| Visonà, A | 1 |
| Lindblad, B | 1 |
| Wakefield, TW | 1 |
| Stanley, TJ | 1 |
| Nichol, BJ | 1 |
| Greenfield, LJ | 1 |
| Stanley, JC | 1 |
| Bergentz, SE | 1 |
| Blanchard, J | 1 |
| Carreras, LO | 1 |
| Kindermans, M | 1 |
| Qian, S | 1 |
| Iwai, T | 1 |
| Signorelli, SS | 1 |
| Cacciaguerra, G | 1 |
| Di Pino, L | 1 |
| Monaco, S | 1 |
| Buttò, G | 1 |
| Sardina, M | 1 |
| Gryglewski, RJ | 1 |
| Korbut, R | 1 |
| Swies, J | 1 |
| Kostka Trabka, E | 1 |
| Bieroń, K | 1 |
| Robak, J | 1 |
| Violi, F | 1 |
| Toplak, H | 1 |
| Bahadori, B | 1 |
| Wascher, TC | 1 |
| Alba, PM | 1 |
| Báez, JM | 1 |
| Paz, A | 1 |
| Monge, M | 1 |
| Mendoza, C | 1 |
| Lechi, C | 1 |
| Gaino, S | 1 |
| Andrioli, G | 1 |
| Paluani, F | 1 |
| Guzzo, P | 1 |
| Bellavite, P | 1 |
| Zatti, M | 1 |
| Jackson, MR | 1 |
| Clagett, GP | 1 |
| Ishida, H | 1 |
| Nakayasu, H | 1 |
| Nukaya, H | 1 |
| Tsuji, K | 1 |
| Quinn, MJ | 1 |
| Fitzgerald, DJ | 1 |
| Kagawa, H | 1 |
| Nomura, S | 1 |
| Nagahama, M | 1 |
| Ozaki, Y | 1 |
| Fukuhara, S | 1 |
| Hirsch, AT | 1 |
| Ringleb, PA | 1 |
| Scheen, AJ | 1 |
| Olin, JW | 2 |
| Black, C | 1 |
| Paterson, KR | 1 |
| Agnelli, G | 1 |
| Leys, D | 1 |
| Duran, E | 1 |
| Canbaz, S | 1 |
| Ege, T | 1 |
| Acipayam, M | 1 |
| Verhaeghe, R | 1 |
| Boissel, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.[NCT00174759] | Phase 3 | 1,460 participants (Anticipated) | Interventional | 2004-09-30 | Completed | ||
| Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| A Phase III Randomized Trial of Warfarin Plus Antiplatelet Therapy Versus Antiplatelet Therapy Alone in Patients With Peripheral Vascular Disease[NCT00125671] | Phase 3 | 2,400 participants | Interventional | 2000-01-31 | Active, not recruiting | ||
| Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-01-09 | Recruiting | ||
| DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease.[NCT04218656] | Phase 4 | 159 participants (Actual) | Interventional | 2020-06-08 | Completed | ||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV[NCT02559414] | Phase 2 | 55 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to endothelial function. (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 14.06 |
| Placebo Follow up | 13.84 |
| Aspirin Baseline | 11.18 |
| Aspirin Randomization | 12.11 |
| Clopidogrel Baseline | 13.06 |
| Clopidogrel Randomization | 12.29 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to immune activity (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 15.53 |
| Placebo Follow up | 15.43 |
| Aspirin Baseline | 13.15 |
| Aspirin Follow up | 14.96 |
| Clopidogrel Baseline | 16.03 |
| Clopidogrel Follow up | 14.85 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to inflammation (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
(NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
The primary objective of these analyses will be to compare the effects of aspirin versus control and clopidogrel versus control for the outcome of platelet activity. Aspirin is expected to decrease arachidonic acid-induced platelet aggregation by 50% versus control. Clopidogrel is expected to decrease ADP-induced platelet aggregation by 50% versus control. (NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 72.35 |
| Placebo Follow up | 79.11 |
| Aspirin Baseline | 72.79 |
| Aspirin Randomization | 26.77 |
| Clopidogrel Baseline | 71.07 |
| Clopidogrel Randomization | 65.00 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
23 reviews available for ticlopidine and Diseases, Peripheral Vascular
| Article | Year |
|---|---|
Aspirin, Plavix, and Other Antiplatelet Medications: What the Oral and Maxillofacial Surgeon Needs to Know.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Medication Therapy Management; Oral Surgical | 2016 |
Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Cardiovascular Diseas | 2009 |
Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Evidence-Based Me | 2009 |
Antiplatelet and antithrombotic treatment of patients with peripheral arterial disease.
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Disease Progression; Dose-Respo | 2010 |
Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases.
Topics: Age Distribution; Aged; Aged, 80 and over; Agranulocytosis; Anemia, Aplastic; Anti-Bacterial Agents; | 2002 |
Epidurals and clopidogrel in peripheral vascular surgery.
Topics: Analgesia, Epidural; Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibit | 2004 |
Peripheral arterial disease. A systemic disease extending beyond the affected extremity.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Exercise; Geriatrics; Humans; Periphe | 2004 |
Antiplatelet therapy in peripheral arterial disease.
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Dipyridamole; Humans; Peripheral Vascular Disease | 2004 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
Emerging drugs in peripheral arterial disease.
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Arteries; Aspirin; Clopidogrel; D | 2006 |
Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Intermittent Claudication; | 2006 |
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
Topics: Angina, Unstable; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Humans; Inflam | 2007 |
Risk reduction with clopidogrel in the management of peripheral arterial disease.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Peripheral Vascular Diseases; Platelet Aggr | 2007 |
Antiplatelet therapy for vascular interventions.
Topics: Angioplasty, Balloon; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Endarterecto | 2008 |
Chronic antithrombotic therapy in post-myocardial infarction patients.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Humans; Myocardial Infarction; Perip | 2008 |
Antithrombotic therapy in peripheral arterial occlusive disease.
Topics: Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Endarterectomy, C | 1998 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bo | 1999 |
New antiplatelet agents: ticlopidine and clopidogrel. Antiplatelet therapy but at what cost?
Topics: Aspirin; Bone Marrow; Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibi | 2001 |
Rationale for the use of platelet aggregation inhibitors in PAD patients.
Topics: Aspirin; Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Randomi | 2001 |
Atherothrombosis--the neurologist's point of view.
Topics: Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Predictive Value | 2001 |
Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy.
Topics: Algorithms; Arteriosclerosis; Aspirin; Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet A | 2002 |
The role of platelets in peripheral arterial disease: therapeutic implications.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Peripheral Vascular Diseases; | 2002 |
[Role of antiaggregants in the treatment of arterial diseases of the lower limbs].
Topics: Humans; Intermittent Claudication; Ketanserin; Leg; Meta-Analysis as Topic; Peripheral Vascular Dise | 1991 |
25 trials available for ticlopidine and Diseases, Peripheral Vascular
| Article | Year |
|---|---|
Discontinuation of preoperative clopidogrel is unnecessary in peripheral arterial surgery.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Peripheral | 2013 |
Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Female; Fibrinolytic Agents; Humans; Kaplan-Meier Es | 2015 |
Patients with peripheral arterial disease in the CHARISMA trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Epidemiologic Method | 2009 |
Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Biomarkers; Blotting, Western; Cell P | 2009 |
Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Catheterization, Per | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Sche | 2010 |
Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients.
Topics: Administration, Oral; Aged; Aspirin; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; | 2012 |
A human model of platelet-leucocyte adhesive interactions during controlled ischaemia in patients with peripheral vascular disease.
Topics: Adult; Arterial Occlusive Diseases; Blood Platelets; Blood Viscosity; Cell Adhesion; Clopidogrel; Do | 2002 |
The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease.
Topics: Aged; Aspirin; Blood Platelets; Cell Size; Clopidogrel; Drug Resistance; Female; Humans; Male; Middl | 2003 |
Combination antiplatelet therapy in patients with peripheral vascular bypass grafts.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Drug T | 2004 |
Leukocyte count as an independent predictor of recurrent ischemic events.
Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leuk | 2004 |
The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease.
Topics: Adenosine Diphosphate; Aged; Arteriosclerosis; Aspirin; Blood Platelets; Cell Shape; Clopidogrel; Dr | 2004 |
Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment.
Topics: Aged; Cerebrovascular Disorders; Clopidogrel; Epidemiologic Methods; Female; Humans; Male; Periphera | 2006 |
Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Biomarkers; Clopidogrel; Collagen; Cross-Ove | 2005 |
Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Cardiovascular Disea | 2006 |
Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Antithrombin III; Aspirin; Blood Platelets; C-Reactive Protein; CD40 Ligand | 2006 |
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease.
Topics: Adult; Aged; Argentina; Double-Blind Method; Female; Follow-Up Studies; Humans; Intermittent Claudic | 1994 |
Three-month therapy with calcium-heparin in comparison with ticlopidine in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class.
Topics: Arterial Occlusive Diseases; Blood Gas Monitoring, Transcutaneous; Exercise Test; Female; Fibrinolyt | 1993 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine après Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurgie.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Double-Blind Method; Female; Graft Occlusion, Vasc | 1997 |
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Fem | 2000 |
[Role of antiaggregants in the treatment of arterial diseases of the lower limbs].
Topics: Humans; Intermittent Claudication; Ketanserin; Leg; Meta-Analysis as Topic; Peripheral Vascular Dise | 1991 |
45 other studies available for ticlopidine and Diseases, Peripheral Vascular
| Article | Year |
|---|---|
Prevalence of nonresponsiveness to aspirin in patients with symptomatic peripheral arterial disease using true point of care testing.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Peripheral Vascular Diseases; Pla | 2014 |
Initial experience with ticagrelor in patients with critical limb ischemia and high on-clopidogrel platelet reactivity undergoing complex peripheral endovascular procedures.
Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Endovascular Procedures | 2014 |
Reply: To PMID 23891491.
Topics: Female; Humans; Male; Peripheral Vascular Diseases; Preoperative Care; Ticlopidine; Vascular Surgica | 2014 |
Regarding "Discontinuation of preoperative clopidogrel is unnecessary in peripheral arterial surgery".
Topics: Female; Humans; Male; Peripheral Vascular Diseases; Preoperative Care; Ticlopidine; Vascular Surgica | 2014 |
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini | 2009 |
Variability of residual platelet function despite clopidogrel treatment in patients with peripheral arterial occlusive disease.
Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Patient Co | 2010 |
Review of an article: Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Jill J.F. Belch, MD, FRCP, John Dormandy, MD, FRCS, and the CASPAR Writing Committee
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Female; Humans; Lower Extremity; Male; Peripheral Vas | 2012 |
Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures.
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Prescriptions; Drug Therapy | 2013 |
Severe bleeding following lumbar sympathetic blockade in two patients under medication with irreversible platelet aggregation inhibitors.
Topics: Aged; Anesthesia, Spinal; Autonomic Nerve Block; Fatal Outcome; Female; Hemorrhage; Humans; Magnetic | 2002 |
Is aspirin still the antiplatelet drug of choice for patients with peripheral arterial disease?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Peripheral Vascul | 2003 |
[Anticoagulation and antiaggregation in patients with peripheral arterial occlusive diseases].
Topics: Administration, Oral; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Bl | 2003 |
[Even when walking yet does not cause any pain, peripheral arterial occlusive disease costs life years].
Topics: Arterial Occlusive Diseases; Clinical Trials as Topic; Clopidogrel; Diabetes Complications; Humans; | 2003 |
Clinical and angiographic outcome after interventional treatment of the iliac arteries with a new carbofilm coated stent: preliminary results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiography; Anticoagulants; Arterial Occlusive Disea | 2004 |
Clopidogrel and vascular disease prevention.
Topics: Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Ticlopidine | 2004 |
Role of antiplatelet therapy in cardiovascular disease III: Peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Clopidogrel; Female; Humans; Intermittent Claudication; M | 2004 |
Development of a score to predict the need for coronary artery bypass graft surgery in patients with non-ST segment elevation acute coronary syndromes.
Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Artery Bypass; Heart Failure; Humans; Logistic Models; | 2004 |
Creative cost-effectiveness analysis of CAPRIE data- dust in our eyes.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Humans; Peripheral Vascular | 2005 |
[Antiplatelet agents and regional anaesthesia: experience in 130 patients].
Topics: Aged; Aspirin; Autonomic Nerve Block; Blood Loss, Surgical; Blood Vessel Prosthesis Implantation; Cl | 2005 |
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.
Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Clopidogrel; Cohort Studies; Ex | 2005 |
The (variable) definition of benefit in the case of clopidogrel vs aspirin.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregat | 2005 |
Effect of YM-254890, a specific Galphaq/11 inhibitor, on experimental peripheral arterial disease in rats.
Topics: Animals; Aorta; Blood Flow Velocity; Blood Pressure; Clopidogrel; Dermis; Dose-Response Relationship | 2006 |
Medical management of peripheral arterial disease.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Humans; Peripheral Vascular Diseases; Phthalic Acids; P | 2006 |
[Impact of the choice of an antiplatelet therapy for peripheral arterial disease: cost-effectiveness ratio and health economics assessment].
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Humans; Peripheral Vascular Diseases; Platelet Aggregat | 2007 |
Rate, degree, and predictors of recovery from disability following ischemic stroke.
Topics: Aged; Brain Ischemia; Causality; Clopidogrel; Cohort Studies; Diabetes Complications; Disability Eva | 2007 |
Determination of clopidogrel main metabolite in plasma: a useful tool for monitoring therapy?
Topics: Aged; Chromatography, High Pressure Liquid; Clopidogrel; Female; Humans; Male; Mass Spectrometry; Pe | 2008 |
Loss of taste with clopidogrel.
Topics: Aged; Ageusia; Clopidogrel; Humans; Male; Peripheral Vascular Diseases; Platelet Aggregation Inhibit | 2008 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |
Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - Portroz (Slovenia) September 2007.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Disease Progression; Exercise Test; Humans; Intermittent Cla | 2008 |
Pharmacological prophylaxis against postoperative graft occlusion after peripheral vascular surgery: a world-wide survey.
Topics: Anticoagulants; Aspirin; Data Collection; Dipyridamole; Drug Utilization; Graft Occlusion, Vascular; | 1995 |
Effect of ticlopidine on the cutaneous circulation in peripheral vascular disease.
Topics: Aged; Blood Gas Monitoring, Transcutaneous; Drug Evaluation; Female; Gangrene; Humans; Intermittent | 1993 |
Thrombolytic action of ticlopidine: possible mechanisms.
Topics: Aged; Animals; Antioxidants; Cats; Fibrinolysis; Fibrinolytic Agents; Free Radical Scavengers; Hemos | 1996 |
CAPRIE trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P | 1997 |
CAPRIE trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P | 1997 |
[Myocardial infarct, stroke and vascular events reduced by a third].
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular | 1997 |
Atypical microangiopathy in a patient treated with ticlopidine.
Topics: Humans; Male; Middle Aged; Peripheral Vascular Diseases; Ticlopidine | 1998 |
Decrease of platelet intracellular pH and adhesion by ticlopidine in patients with vascular disease.
Topics: Aged; Blood Platelets; Calcium; Cytosol; Female; Humans; Hydrogen-Ion Concentration; Male; Periphera | 1998 |
[Prevention in the 21st century. Athero-thrombosis and ischemic events].
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Female; Forecasting; Human | 1998 |
Study of the pharmacological effect of the bile salt, sodium scymnol sulfate, from Rhizoprionodon acutus. III. Protective effect of scymnol against vascular endothelial cell damage in a rat peripheral arterial occlusion model.
Topics: Alanine Transaminase; Animals; Antithrombin III; Arginine; Arterial Occlusive Diseases; Aspartate Am | 1999 |
Effect of ticlopidine on platelet-derived microparticles in patients with connective tissue diseases.
Topics: Antigens, CD; Biomarkers; Blood Platelets; Connective Tissue Diseases; Endothelium, Vascular; Female | 1999 |
Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention.
Topics: Aspirin; Carotid Stenosis; Cost-Benefit Analysis; Diabetes Mellitus; Digestive System; Female; Human | 2000 |
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; D | 2001 |
Antiplatelet therapy: a vascular medicine perspective.
Topics: Aspirin; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Ticlopidine; United | 2000 |
Antiplatelet therapy: a vascular medicine perspective.
Topics: Aspirin; Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Ticlopi | 2000 |
Aspirin versus clopidogrel for synthetic graft patency after peripheral arterial bypass grafting.
Topics: Arteries; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Pe | 2001 |
Prophylactic antiplatelet therapy in peripheral arterial disease.
Topics: Arterial Occlusive Diseases; Arteries; Humans; Leg; Peripheral Vascular Diseases; Platelet Aggregati | 1991 |